Author

Hiroyuki Yoshitsugu

Observed names: H Yoshitsugu, H. Yoshitsugu, Hiroyuki YOSHITSUGU

Institutions: Oita University, MSD K.K. (Japan)

Observed institutions: Oita University, Bristol-Myers Squibb (United States), MSD K.K. (Japan), Bristol-Myers Squibb (Japan)

OpenAlex ID: A5002907712

A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?

2013 · Koji Chiba, Hiroyuki Yoshitsugu, et al. · The Journal of Clinical Pharmacology · 53

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

2013 · Animesh Pardanani, Andrew W. Roberts, et al. · Blood · 25

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

2022 · Keisuke Nakamura, Katsukuni Fujimoto, et al. · Clinical and Translational Science · 19

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects

2018 · Yuki Matsumoto, Tamara Cabalu, et al. · Clinical Pharmacology & Therapeutics · 19

PDF

Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Subjects

2022 · Kazuhiko Asari, Mikio Ishii, et al. · Clinical Pharmacology in Drug Development · 11

Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection

2018 · Makoto Kakara, Kajal Larson, et al. · Journal of Infection and Chemotherapy · 11

PDF

Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection

2022 · Takashi Iwasa, Camila de Almeida, et al. · The Journal of Clinical Pharmacology · 9

Markov Chain Monte Carlo Bayesian Analysis for Population Pharmacokinetics of Dasatinib in Japanese Adult Subjects with Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

2012 · Hiroyuki YOSHITSUGU, Yasuhiko IMAI, et al. · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · 9

PDF

Key fragments for identification of positional isomer pair in glucuronides from the hydroxylated metabolites of RT-3003 (Vintoperol) by liquid chromatography/electrospray ionization mass spectrometry

1999 · Hiroyuki Yoshitsugu, Tetsuo Fukuhara, et al. · Journal of Mass Spectrometry · 7

Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients

2023 · Mikio Ishii, Yuji Orito, et al. · Journal of Infection and Chemotherapy · 6

Integration of Physiologically‐Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity

2015 · L Zhou, J Gan, et al. · CPT Pharmacometrics & Systems Pharmacology · 4

PDF

Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients

2011 · Hiroyuki Yoshitsugu, Takao Sakurai, et al. · Diagnostic Microbiology and Infectious Disease · 3

Identification and Clearance Involved in the Formation of Glucuronides of RT-3003, a New Peripheral Blood Flow Enhancer, and Its Metabolite in Rats.

2000 · Takayuki KABURAGI, Hiroyuki YOSHITSUGU, et al. · Biological and Pharmaceutical Bulletin · 3

PDF

Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity

2024 · Takashi IWASA, Sachiko YAMA, et al. · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · 1

A Phase 1 Study of MK ‐1942, a Negative Allosteric Modulator of mGluR2 , in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype

2026 · Chihiro Hasegawa, Yohei Doi, et al. · Clinical and Translational Science

PDF

Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024)

2026 · Kana Morihisa, Hiroyuki Yoshitsugu, et al. · Clinical and Translational Science

Impact of COVID‒19 Pandemic on Clinical Pharmacology Trials in Japanese Subjects Conducted at Phase 1 Units in Japan or Overseas

2024 · Saori TSUCHIYA, Chieko MUTO, et al. · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics

Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection

2024 · Chihiro Hasegawa, Takashi Iwasa, et al.

3069 Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients

2015 · T. Yoshida, Y. Oya, et al. · European Journal of Cancer

P3‐318: The safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS‐708163 in young and elderly Japanese subjects

2010 · George Ono, Kaoru Kondo, et al. · Alzheimer s & Dementia

Studies on the metabolic fate of TAB, new TPN solutions. Plasma concentration, distribution and excretion in normal and laparotomized rats

1991 · Hiroyuki Nogawa, Hiroyuki Yoshitsugu, et al. · Yakuri to chiryō

Works count: 21

Citation count: 180

H-index: 8

I10-index: 6